Identification of a Prognostic Index Based on a Metabolic-Genomic Landscape Analysis of Hepatocellular Carcinoma (HCC)

Abstract

Background Metabolic disorders have attracted increasing attention from scientists who conduct research on various tumours, especially hepatocellular carcinoma (HCC). The purpose of this study was to assess the prognostic significance of metabolism in HCC. Methods The expression profiles of metabolism-related genes (MRGs) of 349 surviving HCC patients were extracted from The Cancer Genome Atlas (TCGA) database. Subsequently, a series of biomedical computational algorithms were used to identify a seven-MRG signature as a prognostic model. GSEA indicated the function and pathway enrichment of these MRGs. Then, drug sensitivity analysis was used to identify the hub gene, which was tested using IHC staining. Results A total of 420 differential MRGs and 116 differentially expressed transcription factors (TFs) were identified in HCC patients based on data from the TCGA database. The GO and KEGG enrichment analyses indicated that metabolic disturbance might be involved in the development of HCC. LASSO regression analysis was used to construct a seven-MRG signature (DHDH, ENO1, G6PD, LPCAT1, PDE6D, PIGU and PPAT) that could predict the prognosis of HCC patients. GSEA revealed the functional and pathway enrichment of these seven MRGs. Then, drug sensitivity analysis indicated that G6PD might play a key role in the prognosis of HCC by promoting chemoresistance. Finally, we used IHC staining to demonstrate the relationship between G6PD expression levels and clinical parameters in HCC patients. Conclusion The results of this study provide a potential method for predicting the prognosis of HCC patients and avenues for further studies of HCC metabolism. Moreover, the function of G6PD may play a key role in the development and progression of HCC.

Increased DNA Polymerase Epsilon Catalytic Subunit Expression Predicts Tumor Progression and Modulates Tumor Microenvironment of Hepatocellular Carcinoma

“…So, we focused on POLE to further study the early diagnosis and treatment of HCC. In this study, we performed clinicopathological, IHC and survival analyses to explore the potential prognostic value of POLE in hepatocellular carcinoma [25]. We found the significant correlation between elevated POLE expression and higher grade, advanced stage, worse prognosis of HCC and a high risk of recurrence, showing that POLE is of great significance for early clinical diagnosis of HCC.…”

Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics

“…Notably, the purine supply in the S‐phase for DNA replication, governed by the regulation of PPAT, might be pivotal for tumor proliferation 76 . G6PD enrichment, linked to the cell cycle and apoptosis, 77 with the Plk1 (Polo‐like kinase 1)‐mediated activation of G6PD, further underscores its significance in cell cycle regulation 78 . Moreover, tumor cells might induce anomalous splice variants, detrimentally influencing cellular proliferation and angiogenesis 79 .…”

Exploring the Genomic Landscape of Hepatobiliary Cancers to Establish a Novel Molecular Classification System

“…Alterations in this subtype are implicated in proteomic mutation pathways and metabolism of lipids, fats, and amino acids [48,66]. Further investigation is warranted to elucidate how these metabolic genomic alterations influence tumor biology and to potentially discover novel treatments [67].…”